VELLANKI AVANISH enters RAIN ONCOLOGY INC. with 2.50M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Indirect Derivatives
Filed: 4/22/2021ACC: 0000899243-21-016793
DirectorOfficer· President and CEO
Since Apr 2021
2.50M
Baseline shares
94% direct
2.36M
Direct ownership
1 position
57.51K
Derivative underlying
2 instruments
2
Security positions
138.90K indirect
Non-Derivative Holdings2
Common Stock
IndirectShares owned138.90K
Common Stock
DirectShares owned2.36M
Total
2.36M direct·138.90K indirect2.50M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 138.90K | Indirect |
| Common Stock | 2.36M | Direct |
| Total | 2.50M | 2.36M direct·138.90K indirect |
Derivative Holdings2
Series A Preferred Stock
DirectUnderlying security
Common Stock
Underlying shares
11.21K
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
46.30K
Shares owned
N/A
Exercise price
4.00
Expiration
—
Exercise window
—
Total
Underlying
57.51K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Series A Preferred Stock Direct | Common Stock | — | — | 11.21K | N/A | |
| Stock Option (Right to Buy) Direct | Common Stock | 4.00 | — | — | 46.30K | N/A |
| Total | 57.51K | 0.00 | ||||